
BDX Stock Forecast & Price Target
BDX Analyst Ratings
Bulls say
Becton Dickinson is a diversified healthcare company with a strong presence in the United States, making up more than 60% of its revenue. With a focus on high-growth markets, the company's recent separation of its Lifesciences business allows for increased attention on its core medical and connected care units, while also returning cash to shareholders. Despite challenges in China, BD remains well-positioned for future growth and is committed to driving shareholder returns.
Bears say
Becton Dickinson is facing significant risks to delivering on its projected growth, including potential delays in achieving milestones related to the separation of its Biosciences and Diagnostics divisions and ongoing headwinds such as funding cuts and trade tensions. Additionally, competition in all segments, changes in healthcare delivery and reimbursement, and potential economic challenges could impact the company's operations. Despite potential upside from its recent business combination, BD may struggle to achieve its targeted high single-digit growth due to these factors.
This aggregate rating is based on analysts' research of Becton, Dickinson and Co. and is not a guaranteed prediction by Public.com or investment advice.
BDX Analyst Forecast & Price Prediction
Start investing in BDX
Order type
Buy in
Order amount
Est. shares
0 shares